CohBar to Present at the BIO Investor Forum
05 oct. 2020 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Present at the H.C. Wainwright 4th Annual NASH Investor Conference
29 sept. 2020 16h05 HE
|
CohBar, Inc.
MENLO PARK, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Present at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit
10 sept. 2020 16h05 HE
|
CohBar, Inc.
MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Present at the H.C. Wainwright Annual Global Investment Conference
03 sept. 2020 08h45 HE
|
CohBar, Inc.
MENLO PARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Announces Closing of Public Offering of Common Stock and Warrants
28 août 2020 16h05 HE
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 28, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic...
CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants
26 août 2020 08h30 HE
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic...
CohBar Announces Proposed Public Offering of Common Stock and Warrants
25 août 2020 16h55 HE
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic...
CohBar Announces First Subjects Dosed in its Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
24 août 2020 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 24, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Reports Second Quarter 2020 Financial Results and Provides Business Update
13 août 2020 16h03 HE
|
CohBar, Inc.
New positive preliminary preclinical results in ARDS modelCompany to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:...
CohBar Presents New Antifibrotic Data at the American Thoracic Society’s Virtual 2020 Conference
05 août 2020 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...